BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31917616)

  • 21. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
    Dolly SO; Collins DC; Sundar R; Popat S; Yap TA
    Drugs; 2017 May; 77(8):813-827. PubMed ID: 28378229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
    Berge EM; Doebele RC
    Semin Oncol; 2014 Feb; 41(1):110-25. PubMed ID: 24565585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
    Giustini NP; Jeong AR; Buturla J; Bazhenova L
    Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update 2020: Management of Non-Small Cell Lung Cancer.
    Alexander M; Kim SY; Cheng H
    Lung; 2020 Dec; 198(6):897-907. PubMed ID: 33175991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Targets in Non-Small Cell Lung Cancer.
    Park SJ; More S; Murtuza A; Woodward BD; Husain H
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
    Gavralidis A; Gainor JF
    Cancer J; 2020; 26(6):517-524. PubMed ID: 33298723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
    Yu HA; Planchard D; Lovly CM
    Am Soc Clin Oncol Educ Book; 2018 May; 38():726-739. PubMed ID: 30231382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti B; Awad MM
    Cancer J; 2020; 26(6):485-495. PubMed ID: 33298719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
    Abdel Karim N; Kelly K
    Oncologist; 2019 Sep; 24(9):1270-1284. PubMed ID: 30914465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Mhanna L; Guibert N; Milia J; Mazieres J
    Curr Treat Options Oncol; 2019 Jun; 20(7):60. PubMed ID: 31172347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
    Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
    Front Oncol; 2016; 6():112. PubMed ID: 27200298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
    Vecchiarelli S; Bennati C
    Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond
    Farago AF; Azzoli CG
    Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding and targeting resistance mechanisms in NSCLC.
    Rotow J; Bivona TG
    Nat Rev Cancer; 2017 Oct; 17(11):637-658. PubMed ID: 29068003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.